- 註冊時間
- 2023-5-6
- 精華
- 在線時間
- 小時
- 米币
-
- 最後登錄
- 1970-1-1
累計簽到:5 天 連續簽到:1 天
|
發表於 2025-1-4 03:09:02
|
顯示全部樓層
RESPONSE OF MICROPENIS TO TOPICAL TESTOSTERONE AND( T+ _. h" c2 `8 o: v6 t- l
GONADOTROPIN
5 G9 j( E" o% F* ^: r8 gRICHARD C. KLUGO* AND JOSEPH C. CERNY
) x$ d, o* ^1 QFrom the Division of Urology, Henry Ford Hospital, Detroit, Michigan
# ] S. N9 C PABSTRACT. v( E! ~3 T, ~3 ^: u1 |
Five patients were treated with gonadotropin and topical testosterone for micropenis associated0 g$ C; `! g6 n$ e# q) A$ {8 l' L
with hypothalamic hypogonadotropic hypogonadism. All patients received 1,000 units of gonado-
! {' F, N8 w. X- X( h/ s) `tropin weekly for 3 weeks, with a 6-week interval followed by 10 per cent topical testosterone. a# _+ H8 v2 q7 b& {) e+ {
cream twice daily for 3 weeks. Serum testosterone levels were measured and remained equivalent1 K9 o4 K$ z. e
for both modes of therapy. Average penile growth response with gonadotropin was 14.3 per cent
6 F# ^9 [6 y1 ^! V) Rincrease in length and 5.0 per cent increase of girth. Topical testosterone produced an average' ^5 D$ K! s% r @; w
increase of 60 per cent in penile length and 52. 9 per cent in girth. The greatest growth response
6 y7 P5 H. u# l- Roccurred in prepuberal male subjects with a minimal response in postpuberal male subjects. This3 i) g4 G/ X4 t* J: H! v2 e( z
study suggests that 10 per cent topical testosterone cream twice daily will produce effective penile: w$ }9 |5 k5 _7 p4 v3 \
growth. The response appears to be greater in younger children, which is consistent with previ-+ g2 L1 E+ [' A- L0 H' \
ously published studies of age-related 5 reductase activity.
( b6 W7 A3 O8 W4 _+ G( ~Children with microphallus regardless of its etiology will! ~; T* M/ L- b2 U% K' x% d! Y. b
require augmentation or consideration for alteration of exter-& S/ \, C; ?3 k" K+ k
nal genitalia. In many instances urethroplasty for hypo-5 G* c" Q: X3 C: l, `9 Y$ l
spadias is easier with previous stimulation of phallic growth.. o0 L4 J3 C( k5 x# n% R
The use of testosterone administered parenterally or topically
+ I i" ~$ t5 c" Thas produced effective phallic growth. 1- 3 The mechanism of( U* S3 X) T. w6 `
response has been considered as local or systemic. With this
- {, J6 J# a; p ]6 Jin mind we studied 5 children with microphallus for response2 i9 `3 K% M- C
to gonadotropin and to topical testosterone independently.
! m3 ~ X( R Z( `% HMATERIALS AND METHODS- t. G! r. b$ H; E& `! b' x5 @6 x4 W
Five 46 XY male subjects between 3 and 17 years old were/ m Z# N0 _4 j
evaluated for serum testosterone levels and hypothalamic% C. ^: B+ `6 K0 I. O/ A( r& i! O
function. Of these 5 boys 2 were considered to have Kallmann's( H5 P' l# Q* t
syndrome, 1 Prader-Willi syndrome and 2 idiopathic hypotha-7 U, X% |& y) R+ v; ~/ D% S" w- E9 C
lamic deficiency. After evaluation of response to luteinizing% \0 F- W: D" M: S/ p
hormone-releasing hormone these patients were treated with
' V1 I8 c0 I! c' P1,000 units of gonadotropin weekly for 3 weeks. Six weeks: R! l `# B0 W4 h1 \, ]
after completion of gonadotropin therapy 10 per cent topical
" A) o& k. T2 W$ |( d; F8 X) S0 _testosterone was applied to the phallus twice daily for 3 weeks.) d/ n% F5 f8 k5 ?3 ~! y
Serum testosterone, luteinizing hormone and follicle-stimulat-
6 t* y' n) W$ Ding hormone were monitored before, during and after comple-8 S6 A+ i& B4 E" @) F4 d
tion of each phase of therapy. Penile stretch length was
% J9 T7 Y# O( kobtained by measuring from the symphysis pubis to the tip of
. D' w |. q/ g& ~. ^) Mthe glans. Penile circumferential (girth) measurements were# @5 ~, l4 h3 p9 ~; l) H6 A
obtained using an orthopedic digital measuring device (see
1 B2 ] E* D6 Q: F4 O/ l$ U. p! [figure).% e/ J1 f' i$ o, {& W2 U
RESULTS
0 `4 g m8 B6 J: ]% HSerum testosterone increased moderately to levels between7 r3 J3 q: R6 D- `" r
50 and 86 ng./dl. with gonadotropin stimulation. Serum testos-4 s" X! q6 r# Y$ }( T% t. Y& _! c3 Z
terone levels with topical testosterone remained near pre-/ V1 L, b4 |2 U
treatment levels (35 ng./dl.) or were elevated to similar levels1 e) m) R3 I" G: d/ v
developed after gonadotropin therapy (96 ng./dl.). Higher
" m) J3 f* `( K( h0 Lserum levels were noted in older patients (12 and 17 years old),
3 @/ ?( Q) g: b. k6 j( [& @while lower levels persisted in younger patients (4, 8, and 10
% ~9 {* F- I" }( p$ U/ Nyears old) (see table). Despite absence of profound alterations
5 B! {2 U) T h( B/ sof serum testosterone the topical therapy provided a greater
; a4 V' X* H' q( N* t* \: s9 [Accepted for publication July 1, 1977. ·
5 N t Y: d# ]! o9 C" y" f( {Read at annual meeting of American Urological Association,3 y) t4 z5 [* v
Chicago, Illinois, April 24-28, 1977.
2 d0 S: l0 f5 p( u: V+ q& X, [* Requests for reprints: Division of Urology, Henry Ford Hospital,, c5 l& B8 u5 q8 B/ c
2799 W. Grand Blvd., Detroit, Michigan 48202.
/ {( n) J, U9 wimprovement in phallic growth compared to gonadotropin.$ P8 d0 [: h% S$ r! K1 r' {
Average phallic growth with gonadotropin was 14.3 per cent
8 I3 ~7 W4 g5 s3 w0 e! ]4 rincrease in length and 5.0 per cent increase of girth. Topical
( b$ L$ j! h* v4 gtestosterone produced a 60.0 per cent increase of phallic length4 E" G( b9 \1 W2 r( ]
and 52.9 per cent increase of girth (circumference). The2 r1 w' k3 p5 J# B- S7 ^, t' ]+ @ M
response to topical testosterone was greatest in children be-* ?. ~. [6 ^) ]2 X, j- `
tween 4 and 8 years old, with a gradual decrease to age 17; ~9 V7 {: L: _) T- w8 E6 B
years (see table).
7 t9 F' v* t$ F7 u4 zDISCUSSION
% H( Q( c0 w! ]% sTopical testosterone has been used effectively by other" Y/ L: e- e$ ^$ d6 q
clinicians but its mode of action remains controversial. Im-
# ~% i5 @( t- f% h) C7 ^% m, umergut and associates reported an excellent growth response" b4 O; t! @" C7 p
to topical testosterone with low levels of serum testosterone,
. H/ I3 ]) d, @, W+ W% Esuggesting a local effect.1 Others have obtained growth re-/ m! @! f; n( N- D( j! } X C
sponse with high. levels of serum testosterone after topical4 H p' o Z" b4 m' a% V
administration, suggesting a systemic response. 3 The use of
' c& r) a- h% k6 Rgonadotropin to obtain levels of serum testosterone compara-: k4 O. ^! \3 P) ^% @' g; H4 d0 D
ble to levels obtained with topical testosterone would seem to/ C ?/ ?: X; T O: x3 L& b
provide a means to compare the relative effectiveness of' U& @0 f9 T& }4 A* p: H
topical testosterone to systemic testosterone effect. It cer-
* M4 X. }- \2 P4 t% X3 i' J6 ]tainly has been established that gonadotropin as well as par-% u+ j4 m* f/ {9 R
enteral testosterone administration will produce genital
* x. z' a8 }- y) l, b7 {% |growth. Our report shows that the growth of the phallus was6 J+ o" o6 e: A4 y5 R* }
significantly greater with topical applications than with go-
: E4 B0 |& q" {0 c, ^$ Rnadotropin, particularly in children less than 10 years old.; o( Q5 O/ o* g. P0 s' {4 n
The levels of serum testosterone remained similar or lower& F0 M9 P( o2 Q. f q* E% n
than with gonadotropin during therapy, suggesting that topi-, j* U, k$ \) I& ]( d" [
cal application produces genital growth by its local effect as
" T& E+ a4 j$ E a5 bwell as its systemic effect.
# z) I! K2 E( c {4 oReview of our patients and their growth response related to
5 |) G7 e& I+ I; ^age shows a greater growth response at an earlier age. This is. d, B# G& {2 h9 @1 {5 N& C
consistent with the findings of Wilson and Walker, who/ K/ T V, F; j8 E; f
reported an increased conversion of testosterone to dihydrotes-
) H. d) \& T8 ^) _" t7 Ytosterone in the foreskin of neonates and infants.4 This activ-
# n& k; `* l4 City gradually decreases with age until puberty when it ap-
: K! K4 g* M, }$ hproaches the same level of activity as peripheral skin. It may) P! s+ C0 f9 o8 ]3 ^! ?% L5 X1 n. T
well be that absorption of testosterone is less when applied at
$ e- }( @7 I+ R z" ^( Dan earlier age as suggested by lower serum levels in children: @; x# b: V0 P$ K A$ l
less than 10 years old. This fact may be explained by the9 R# s4 a2 i, ]) c x
greater ability of phallic skin to convert testosterone to dihy-8 @% m" _- [3 G7 b
drotestosterone at this age. Conversely, serum levels in older1 w# M& U4 T }0 Y) ]# ^. z; @
patients were higher, possibly because of decreased local4 ?4 Y, v. u+ A" `) p
667" s( ~# j$ W' B4 B' c& |
668 KLUGO AND CERNY2 L5 e* F5 Z- D% q) t+ h$ M* |' k
Pt. Age
/ h. {: r/ C& p" p/ H% ~+ a(yrs.)
@4 h C2 S! I2 a1 B+ y! m0 ESerum Testosterone Phallus (cm.) Change Length3 x' W& Y ~* |5 G7 [* }
(ng./dl.) Girth x Length (%)
% q" K! V4 O/ w( v4: |: L5 i2 c o+ t
8' q/ Q& S4 r( z; @( ]
10* P, B9 }3 v8 C
12
8 e1 ]8 {; D' _178 e# L; _0 J- P7 G; p
Gonadotropin
/ y& ^/ m- e+ U2 l/ t71.6 2.0 X 3 16.6& W3 H, N, S. ?
50.4 4.0 X 5.0 20.0* D7 l; a0 u, I7 Y% u" x
22.0 4.5 X 4.0 25.08 t9 n7 b" i5 O
84.6 4.0 X 4.5 11.1
8 x4 U# L0 _" S9 r85.9 4.5 X 5.5 9.0( ]+ ~' E+ M0 H9 F# V, r. O0 `
Av. 14.3
1 s7 s/ w6 r& A* g0 `48 I1 C3 h3 o/ P
8. v" d7 a1 {3 k
10
4 e- q5 |2 W L$ {12
' w$ X3 Q5 V6 b% w5 f170 Q3 F f% c: J* R; n
Topical testosterone3 U' f; ?0 [5 A7 L1 O
34.6 4.5 X 6.5 85) t& }& a' L$ I) k+ J. e
38.8 6.0 X 8.5 707 [+ |- }/ o) N1 d
40.0 6.0 X 6.5 62.58 z' O3 k# ]) G4 p
93.6 6.0 X 7.0 55.5
( }) b2 D4 u$ q6 e8 @6 ^95.0 6.5 X 7.0 27.2+ P, s0 q/ L* Y5 r# n
Av. 60.0$ a$ [/ q9 J0 J, ]& j
available testosterone. Again, emphasis should be placed on
0 @4 w, G# b) K) p9 V1 I3 ]early therapy when lower levels of testosterone appear to& v, d! q9 N1 b! @, S
provide the best responses. The earlier therapy is instituted
0 s6 K( V# X7 ?% W! s2 cthe more likely there will be an excellent response with low$ k( ]+ x& B0 K3 S( J4 v3 i- W5 k& M
serum levels. Response occurs throughout adolescence as" ^) y. ]9 q L1 B9 b6 e, m0 o2 i
noted in nomograms of phallic growth. 7 The actual response/ c/ N* c' I$ i0 b5 J8 x, S% ~9 A
to a given serum level of testosterone is much greater at birth
& o% j) ?& U) Z4 W/ C' o yand gradually decreases as boys reach puberty. This is most
3 D! E; h- z8 U5 P8 x- W. v3 o clikely related to the conversion of testosterone to dihydrotes-
! n& }* j6 e3 s& H8 w8 ]tosterone and correlates well with the studies of testosterone9 k9 s6 N, h) T- u" Y, E3 R
conversion in foreskin at various ages.
# @1 b6 w* T, O' A! j" k" f+ ?The question arises regarding early treatment as to whether/ ~& V$ N) }# G3 ~/ Z/ T+ f
one might sacrifice ultimate potential growth as with acceler-, P1 D# y) P l/ g
ated bone growth. The situation appears quite the reverse
" P1 c6 T8 N/ B k* S1 f( Z; q" Nwith phallic response. If the early growth period is not used
: R- C) J) f, @( P1 K' K( M8 E( Uwhen 5a reductase activity is greatest then potential growth2 F& J/ ^' x# P% K. c7 g8 r
may be lost. We have not observed any regression of growth+ X2 y/ M( I8 D5 B6 s
attained with topical or gonadotropin therapy. It may well
/ ?; B: O) `/ ]8 u2 Abe that some patients will show little or no response to any
0 v6 X2 q* @3 G1 Hform of therapy. This would suggest a defect in the ability to" J2 o1 s5 \/ |1 d0 {
convert testosterone to dihydrotestosterone and indicate that
" u. K$ a' X/ k4 U% Jphallic and peripheral skin, and subcutaneous tissue should
. O* N6 H* f5 O' mbe compared for 5a reductase activity.2 U+ O3 ~0 A, m# T& e' \' J$ b* E
A, loop enlarges to measure penile girth in millimeters. B,
: a! B$ ~9 F# j" zexample of penile girth computed easily and accurately.+ F6 z: {7 L4 @3 g0 N
conversion of testosterone to dihydrotestosterone. It is in this( C- p* s a( |8 Z8 E' _
older group that others have noted high levels of serum! Q _. A) v& D: X C1 r
testosterone with topical application. It would also appear
0 ]0 n4 k# u! O2 s; Hthat phallic response during puberty is related directly to the0 V# g, E0 H8 \, ?9 b" A$ ]7 o
serum testosterone level. There also is other evidence of local; @$ S- f+ L. Z) ^0 Y4 L4 ^
response to testosterone with hair growth and with spermato-
) Q- ^ P- t7 @6 H! Hgenesis. 5• 6
+ \/ x9 G2 W% @/ k. M x2 c$ BAdministration of larger doses of gonadotropin or systemic
* L/ S3 q: c$ w4 H I( Ztestosterone, as well as topical applications that produce
- U e3 A, m# Hhigher levels of serum testosterone (150 to 900 ng./dl.), will
: ?' A* r, n' y6 yalso produce phallic growth but risks accelerated skeletal
3 U. I- O2 N1 P' z6 mmaturation even after stopping treatment. It would appear
# G: s4 C9 o$ e( _) h lthat this may be avoided by topical applications of testosterone
z. w: W! v$ X. Yand monitoring of serum testosterone. Even with this control
6 u5 U t! ]3 P0 uthe duration of our therapy did not exceed 3 weeks at any! d* t& G) V( e6 S2 n% L
time. It is apparent that the prepuberal male subject may2 T6 c: ^, x( W
suffer accelerated bone growth with testosterone levels near
9 K5 p1 G$ \% ^8 Q, \200 ng./dl. When skeletal maturation is complete the level of$ U |. ~0 [" X
serum testosterone can be maintained in the 700 to 1,300 ng./
* N5 V4 K$ ~0 b. Mdl. range to stimulate phallic growth and secondary sexual' Z8 w* W. A- A. p: u4 Y
changes. Therefore, after skeletal maturation parenteral tes-! f- }; ^! a8 ]- k% ^& x7 `
tosterone may be used to advantage. Before skeletal matura-, `% O, i3 ]' U/ ~7 Z) Z
tion care must be taken to avoid maintaining levels of serum) n7 G1 b3 k h
testosterone more than 100 ng./dl. Low-dose gonadotropin
7 J$ X8 r" m' \ hdepends upon intrinsic testicular activity and may require8 Y; T" L6 E& g: O* T
prolonged administration for any response.- M& G1 M1 C( [% h
Alternately, topical testosterone does not depend upon tes- N. @) O4 U# _6 J% s3 I! p
ticular function and may provide a more constant level of
) C9 ^: L7 j: F' f+ n& D LREFERENCES
5 Y* ]4 y Z' W0 s5 G- H: F1. Immergut, M., Boldus, R., Yannone, E., Bunge, R. and Flocks,
. Q* l4 a/ z3 Z' |, GR.: The local application of testosterone cream to the prepub-" f& e; a' C1 `6 [. }
ertal phallus. J. Urol., 105: 905, 1971.
% c( Y1 u# f! |8 A# U, \2. Guthrie, R. D., Smith, D. W. and Graham, C. B.: Testosterone
+ I( c+ Y# x/ O/ b7 X$ ltreatment for micropenis during early childhood. J. Pediat.,
$ o" Q# y3 O8 h( ?6 {9 V1 ?6 t83: 247, 1973.
, l3 W8 e: e( I# J4 w3. Jacobs, S. C., Kaplan, G. W. and Gittes, R. F.: Topical testoster-$ S# e- w% i! [
one therapy for penile growth. Urology, 6: 708, 1975.1 b4 d1 H0 I" c4 Z9 ]
4. Wilson, J. D. and Walker, J. D.: The conversion of testosterone3 ~& N+ G7 w. Y1 ~, ]
to 5 alpha-androstan-17 beta-01-3-one (dihydrotestosterone) by, }2 T* n5 D: v8 D' E) n$ ^! _
skin slices of man. J. Clin. Invest., 48: 371, 1969.% E$ m. \/ l p) T" O- v
5. Papa, C. M. and Klingman, A. M.: Stimulation of hair growth2 ~3 t7 }; W! b8 _3 `
by topical application of androgens. J.A.M.A., 191: 521, 1965.
) g) C. q e# g; B5 g% [6. Gittes, R. F., Smith, G., Conn, C. A. and Smith, F.: Local
1 F2 w8 _8 @0 ~6 gandrogenic effect of interstitial cell tumor of the testis. J.5 N* ]7 h; p: _# y3 ?( G$ a: h
Urol., 104: 774, 1970.
( N2 ~' t- ~1 G7 ^# M' t" p$ N7. Schonfeld, W. A. and Beebe, G. W.: Normal growth and varia-2 g$ P# m2 U& F
tion in the male genitalia from birth to maturity. J. Urol., 48: |
|